Wednesday , December 13 2017
Home / Therapies / SGLT-2 Therapy Center (page 2)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Exclusive: Dr Bruce Neal Discusses Canagliflozin’s Potential for Heart Failure Prevention

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.

Read More »